| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ABCB11 |
| Uniprot No | O95342 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1033-1321aa |
| 氨基酸序列 | RAFSYTPSYAKAKISAARFFQLLDRQPPISVYNTAGEKWDNFQGKIDFVDCKFTYPSRPDSQVLNGLSVSISPGQTLAFVGSSGCGKSTSIQLLERFYDPDQGKVMIDGHDSKKVNVQFLRSNIGIVSQEPVLFACSIMDNIKYGDNTKEIPMERVIAAAKQAQLHDFVMSLPEKYETNVGSQGSQLSRGEKQRIAIARAIVRDPKILLLDEATSALDTESEKTVQVALDKAREGRTCIVIAHRLSTIQNADIIAVMAQGVVIEKGTHEELMAQKGAYYKLVTTGSPIS |
| 预测分子量 | 35.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ABCB11重组蛋白的3篇文献摘要示例(注：文献信息为模拟示例，具体内容请根据实际研究补充)：
---
1. **文献名称**: *Functional characterization of ABCB11 mutations in progressive familial intrahepatic cholestasis*
**作者**: Hayashi H, et al.
**摘要**: 本研究通过重组表达人ABCB11蛋白于昆虫细胞系统，分析了多种致病突变对BSEP转运活性的影响，揭示了突变导致胆汁酸外排功能缺陷的分子机制，为遗传性胆汁淤积症提供病理依据。
2. **文献名称**: *Recombinant BSEP expression in mammalian cells: a tool for drug-induced cholestasis screening*
**作者**: Stieger B, et al.
**摘要**: 研究利用HEK293细胞体系表达重组ABCB11蛋白，建立体外药物抑制模型，评估多种药物对BSEP转运活性的抑制作用，为药物肝毒性评估提供高通量筛选平台。
3. **文献名称**: *Purification and reconstitution of human ABCB11 for structural studies*
**作者**: Dawson RJ, Locher KP
**摘要**: 报道了从哺乳动物细胞中纯化重组ABCB11蛋白并重构至脂质体的方法，结合冷冻电镜技术解析其三维结构，揭示了BSEP与胆汁酸结合的分子基础及转运循环机制。
---
如需具体文献，建议通过PubMed或Google Scholar检索关键词“ABCB11 recombinant”、“BSEP expression”获取近期研究。
ABCB11. also known as the bile salt export pump (BSEP), is an ATP-binding cassette (ABC) transporter predominantly expressed in the liver. It localizes to the canalicular membrane of hepatocytes and plays a critical role in biliary secretion by exporting bile salts—a key step in lipid digestion and cholesterol homeostasis. Dysfunction of ABCB11 due to genetic mutations is linked to severe cholestatic disorders, such as progressive familial intrahepatic cholestasis type 2 (PFIC2), and is implicated in drug-induced liver injury (DILI) caused by certain therapeutics that inhibit its activity.
Recombinant ABCB11 protein is engineered to study its biological functions, disease mechanisms, and interactions with drugs. Produced via heterologous expression systems (e.g., insect or mammalian cells), the recombinant protein retains structural and functional integrity, enabling in vitro analysis of transport kinetics, substrate specificity, and inhibitor effects. Its purification often involves affinity tags and detergent solubilization to maintain membrane protein stability. Research applications include screening compounds for BSEP inhibition (a regulatory requirement in drug development), characterizing pathogenic mutations, and exploring therapeutic strategies like chaperone therapy. Additionally, ABCB11 serves as a model protein for understanding ABC transporter dynamics, aiding structural studies (e.g., cryo-EM) to resolve mechanisms of substrate translocation and ATP hydrolysis. Recombinant ABCB11 thus bridges basic research and clinical translation, offering insights into cholestasis pathophysiology and fostering safer pharmacotherapy.
×
